Sutro Biopharma, Inc.

NasdaqGM:STRO Voorraadrapport

Marktkapitalisatie: US$266.4m

Sutro Biopharma Beheer

Beheer criteriumcontroles 2/4

De CEO Sutro Biopharma is Bill Newell, benoemd in Jan2009, heeft een ambtstermijn van 15.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.13M, bestaande uit 32.2% salaris en 67.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.41% van de aandelen van het bedrijf, ter waarde $ 1.09M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 5.4 jaar.

Belangrijke informatie

Bill Newell

Algemeen directeur

US$2.1m

Totale compensatie

Percentage CEO-salaris32.2%
Dienstverband CEO15.8yrs
Eigendom CEO0.4%
Management gemiddelde ambtstermijn1.8yrs
Gemiddelde ambtstermijn bestuur5.4yrs

Recente managementupdates

We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right

May 31
We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right

Recent updates

Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive

Oct 11
Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

Sep 23

There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise

Aug 24
There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise

Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts

Aug 22
Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts

Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results

Aug 16
Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results

The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%

Jun 26
The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%

We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right

May 31
We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right

Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates

Apr 02
Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates

The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet

Mar 28
The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet

Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%

Dec 19
Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%

Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?

Aug 24
Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?

Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?

Feb 10
Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?

An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued

Jan 12
An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued

Sutro Biopharma: Partnership Progress Warrants Exposure

Aug 16

New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)

Aug 11
New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)

Sutro Biopharma GAAP EPS of -$0.55, revenue of $28.1M

Aug 08

Sutro to get $10M payment from Merck after first patient dosed in collaboration trial

Jul 26

Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?

May 02
Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?

Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching

Dec 27

Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?

Dec 26
Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?

Sutro Biopharma initiated buy at H.C. Wainwright citing ADC candidates

Jun 18

Industry Analysts Just Made A Sizeable Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts

May 09
Industry Analysts Just Made A Sizeable Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts

Analyse CEO-vergoeding

Hoe is Bill Newell's beloning veranderd ten opzichte van Sutro Biopharma's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$124m

Mar 31 2024n/an/a

-US$115m

Dec 31 2023US$2mUS$687k

-US$107m

Sep 30 2023n/an/a

-US$172m

Jun 30 2023n/an/a

-US$143m

Mar 31 2023n/an/a

-US$130m

Dec 31 2022US$3mUS$663k

-US$119m

Sep 30 2022n/an/a

-US$123m

Jun 30 2022n/an/a

-US$134m

Mar 31 2022n/an/a

-US$114m

Dec 31 2021US$6mUS$625k

-US$106m

Sep 30 2021n/an/a

-US$127m

Jun 30 2021n/an/a

-US$79m

Mar 31 2021n/an/a

-US$43m

Dec 31 2020US$2mUS$554k

-US$32m

Sep 30 2020n/an/a

US$13m

Jun 30 2020n/an/a

-US$17m

Mar 31 2020n/an/a

-US$61m

Dec 31 2019US$4mUS$497k

-US$56m

Sep 30 2019n/an/a

-US$42m

Jun 30 2019n/an/a

-US$40m

Mar 31 2019n/an/a

-US$38m

Dec 31 2018US$9mUS$482k

-US$35m

Sep 30 2018n/an/a

-US$49m

Jun 30 2018n/an/a

-US$40m

Mar 31 2018n/an/a

-US$30m

Dec 31 2017US$703kUS$468k

-US$20m

Compensatie versus markt: De totale vergoeding ($USD 2.13M ) Bill } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.46M ).

Compensatie versus inkomsten: De vergoeding van Bill is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Bill Newell (66 yo)

15.8yrs

Tenure

US$2,129,980

Compensatie

Mr. William J. Newell, also known as Bill, J.D. has been the Chief Executive Officer and Director of Sutro Biopharma, Inc. since February 2009. He served as Independent Director at Vaxcyte, Inc. since Nove...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
William Newell
CEO & Director15.8yrsUS$2.13m0.41%
$ 1.1m
Hans-Peter Gerber
Chief Scientific Officer1.2yrsUS$1.63m0.029%
$ 78.4k
Anne Borgman-Hagey
Chief Medical Officer1.8yrsUS$2.34m0.030%
$ 79.2k
Jane Chung
President & COOless than a yearUS$1.43m0.066%
$ 176.3k
James Swartz
Founderno datageen gegevensgeen gegevens
Edward Albini
CFO & Secretary11.8yrsUS$2.08m0.13%
$ 346.9k
Venkatesh Srinivasan
Chief Technical Operations Officer1.5yrsgeen gegevens0.039%
$ 103.1k
David Pauling
General Counsel3.7yrsgeen gegevensgeen gegevens
Linda Fitzpatrick
Chief People & Communications Officer16.8yrsUS$1.30m0.10%
$ 270.8k
Barbara Leyman
Chief Business Development Officerless than a yeargeen gegevensgeen gegevens
Regina Cheng
Vice President & Controllerno datageen gegevensgeen gegevens

1.8yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van STRO wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

NaamPositieTenureCompensatieEigendom
William Newell
CEO & Director15.8yrsUS$2.13m0.41%
$ 1.1m
Connie Matsui
Independent Chair of the Board5.4yrsUS$173.11k0%
$ 0
James Panek
Independent Director4.8yrsUS$138.11k0%
$ 0
John Freund
Independent Director10.8yrsUS$138.11k0.069%
$ 183.1k
Daniel Petree
Independent Director15.3yrsUS$140.11k0.027%
$ 73.0k
Trevor Hallam
Member of Scientific Advisory Board1.8yrsUS$1.53m0.12%
$ 326.2k
Carlos Paya
Chair of the Scientific Advisory Board4.5yrsgeen gegevensgeen gegevens
Michael Dybbs
Independent Director6.3yrsUS$133.11k0%
$ 0
Joseph Lobacki
Independent Director7.8yrsUS$152.11k0%
$ 0
Lawrence Fong
Co-Chair of Clinical Advisory Board & Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Lainie Martin
Member of the Clinical Advisory Board4.5yrsgeen gegevensgeen gegevens
Heidi Hunter
Independent Director3yrsUS$150.28k0%
$ 0

5.4yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van STRO wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.4 jaar).